The relatively low concentrations that produced the individual drug sensitivities combined with the synergism in Brca1-/- MMECs provides strong preclinical evidence for the cisplatin-gemcitabine combination in the treatment of BRCA1-associated breast cancers. The gene discussed is BRCA1; the disease is breast carcinoma.